Research Analysts Offer Predictions for USNA FY2025 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Investment analysts at Sidoti Csr lifted their FY2025 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research report issued to clients and investors on Thursday, January 15th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings per share of $1.74 for the year, up from their previous estimate of $1.73. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2025 earnings at $0.41 EPS, Q1 2027 earnings at $0.65 EPS, Q2 2027 earnings at $0.67 EPS, Q3 2027 earnings at $0.74 EPS and FY2027 earnings at $2.81 EPS.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Wednesday, October 22nd. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.62). The company had revenue of $213.67 million during the quarter, compared to analysts’ expectations of $224.97 million. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.97%. USANA Health Sciences has set its FY 2025 guidance at 1.730-1.730 EPS.

A number of other analysts have also recently commented on USNA. Zacks Research cut shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 7th. Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $36.00.

USANA Health Sciences Stock Up 1.6%

USNA stock opened at $21.96 on Friday. The business has a 50 day moving average of $19.85 and a 200-day moving average of $25.31. The firm has a market cap of $401.34 million, a PE ratio of 24.95, a P/E/G ratio of 0.95 and a beta of 0.65. USANA Health Sciences has a 12-month low of $18.48 and a 12-month high of $38.32.

Insider Activity

In other USANA Health Sciences news, Director Frederic J. Winssinger sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $19.21, for a total transaction of $38,420.00. Following the transaction, the director owned 5,986 shares in the company, valued at approximately $114,991.06. This represents a 25.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Turman Fleming sold 1,750 shares of USANA Health Sciences stock in a transaction dated Friday, October 31st. The shares were sold at an average price of $19.79, for a total transaction of $34,632.50. Following the transaction, the director directly owned 4,565 shares of the company’s stock, valued at approximately $90,341.35. This trade represents a 27.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 5,680 shares of company stock valued at $114,090. Corporate insiders own 0.63% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP raised its holdings in shares of USANA Health Sciences by 349.8% in the third quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock worth $4,434,000 after buying an additional 125,158 shares during the period. Pzena Investment Management LLC grew its position in USANA Health Sciences by 9.4% in the 2nd quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company’s stock valued at $36,583,000 after acquiring an additional 103,074 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in USANA Health Sciences by 202.3% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 97,537 shares of the company’s stock worth $2,978,000 after purchasing an additional 65,268 shares during the period. Ameriprise Financial Inc. lifted its position in shares of USANA Health Sciences by 64.6% during the second quarter. Ameriprise Financial Inc. now owns 150,090 shares of the company’s stock worth $4,582,000 after purchasing an additional 58,921 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of USANA Health Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after purchasing an additional 57,249 shares during the period. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.